Expert Insights

Alexander Spira, MD, PhD, FACP, discussed post-progression results from the phase 3 MARIPOSA-2 trial, as presented at the European Lung Cancer Congress 2024.

Sudha Sundar, MBBS, MPhil, discussed results from the ROCkeTS study, as presented at the SGO 2024 Annual Meeting, which compared the accuracy of various risk prediction models for diagnosing ovarian cancer.

Aine Clements, MD, discussed ancillary results from phase 3 GOG-0258 trial, as presented at the SGO 2024 Annual Meeting which demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial...

At the SGO 2024 Annual Meeting, Alison Schram, MD, discussed results from the PYNNACLE study which assessed the clinical efficacy of rezatapopt among heavily pre-treated patients with advanced ovarian cancer harboring a TP53-Y220C mutation.

Joshua Sabari, MD, discussed post-progression secondary end points from the phase 3 PAPILLON trial evaluating amivantamab plus chemotherapy among patients with advanced EGFR-mutated non-small cell lung cancer, as presented at the European...

At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.

At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.

At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...

At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...